In Vitro & In Vivo Diagnostic Substances · DE · CIK 1652130
Intellia Therapeutics revolutionizes medicine by developing curative CRISPR gene editing treatments for severe diseases
Comparable business profile · signals at a glance
Coverage (30d): 1 reputable article · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Mar 2, 2026: 1 insider bought $1.4M · 7 sold $1.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Basta JamesEVP, General Counsel | Sell | 1,211 | $13.78 | $17K |
| Mar 2, 2026 | Clark ElianaEVP, Chief Technical Officer | Sell | 607 | $13.78 | $8K |
| Jan 5, 2026 | Cohen Fred EDirector | Buy | 150,000 | $9.35 | $1.4M |
| Jan 5, 2026 | Leonard John MPresident and CEO | Sell | 34,146 | $9.21 | $314K |
| Jan 5, 2026 | Lebwohl DavidEVP, Chief Medical Officer | Sell | 11,903 | $9.21 | $110K |
| Jan 5, 2026 | Basta JamesEVP, General Counsel | Sell | 10,397 | $9.21 | $96K |
| Jan 5, 2026 | Clark ElianaEVP, Chief Technical Officer | Sell | 9,515 | $9.21 | $88K |
| Jan 5, 2026 | Schultes Birgit CEVP, Chief Scientific Officer | Sell | 8,508 | $9.21 | $78K |
| Jan 5, 2026 | Dulac Edward J IiiEVP, Chief Financial Officer | Sell | 6,379 | $9.21 | $59K |
| Jan 5, 2026 | Dube Michael PVP, Chief Accounting Officer | Sell | 2,989 | $9.21 | $28K |
| Dec 11, 2025 | Leonard John MPresident and CEO | Sell | 49,959 | $9.49 | $474K |
| Dec 11, 2025 | Leonard John MPresident and CEO | Sell | 32,832 | $9.47 | $311K |
| Dec 11, 2025 | Leonard John MPresident and CEO | Sell | 5,355 | $9.59 | $51K |
| Oct 1, 2025 | Dube Michael PVP, Chief Accounting Officer | Sell | 1,871 | $17.38 | $33K |
| Oct 1, 2025 | Schultes Birgit CEVP, Chief Scientific Officer | Sell | 31 | $17.38 | $539 |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.